minocycline and Brain-Damage--Chronic

minocycline has been researched along with Brain-Damage--Chronic* in 2 studies

Other Studies

2 other study(ies) available for minocycline and Brain-Damage--Chronic

ArticleYear
Minocycline attenuates white matter damage in a rat model of chronic cerebral hypoperfusion.
    Journal of neuroscience research, 2006, Feb-01, Volume: 83, Issue:2

    White matter lesions are thought to result from chronic cerebral ischemia and constitute a core pathology of subcortical vascular dementia. This rarefaction has been known to be associated with microglial activation. We investigated whether minocycline, a microglial inhibitor, attenuates the white matter damage induced by chronic cerebral hypoperfusion that is used as a model of vascular dementia. Male Wistar rats were subjected to bilateral, permanent occlusion of the common carotid arteries (BCCAO) to induce chronic cerebral hypoperfusion. Minocycline or saline was injected daily for 2 weeks after BCCAO. In the corpus callosum and the optic tract, white matter damage observed with Klüver-Barrera staining was significantly attenuated in the minocycline-treated group compared to saline-treated controls. In control rats, immunoreactivities of major basic protein (MBP), Ox-42 as a microglial marker, and matrix metalloproteinase (MMP)-2 were increased in the corpus callosum. Minocycline significantly reduced these changes. Co-expression of Ox-42 and MMP-2 was confirmed by double immunofluorescence histochemistry. Our results suggest that chronic treatment with minocycline could be protective against at least some ischemic white matter damage, and its mechanism may be related to suppressing microglial activation.

    Topics: Analysis of Variance; Animals; Brain Damage, Chronic; CD11b Antigen; Corpus Callosum; Dementia, Vascular; Diagnostic Imaging; Disease Models, Animal; Drug Administration Schedule; Glial Fibrillary Acidic Protein; Immunohistochemistry; Male; Matrix Metalloproteinase 2; Minocycline; Myelin Basic Protein; Rats; Rats, Wistar; Visual Pathways

2006
Minocycline attenuates hypoxia-ischemia-induced neurological dysfunction and brain injury in the juvenile rat.
    The European journal of neuroscience, 2006, Volume: 24, Issue:2

    To investigate whether minocycline provides long-lasting protection against neonatal hypoxia-ischemia-induced brain injury and neurobehavioral deficits, minocycline was administered intraperitoneally in postnatal day 4 Sprague-Dawley rats subjected to bilateral carotid artery occlusion followed by exposure to hypoxia (8% oxygen for 15 min). Brain injury and myelination were examined on postnatal day 21 (P21) and tests for neurobehavioral toxicity were performed from P3 to P21. Hypoxic-ischemic insults resulted in severe white matter injury, enlarged ventricles, deficits in the hippocampus, reduction in numbers of mature oligodendrocytes and tyrosine hydroxylase-positive neurons, damage to axons and dendrites, and impaired myelination, as indicated by the decrease in myelin basic protein immunostaining in the P21 rat brain. Hypoxic-ischemic insult also significantly affected physical development (body weight gain and eye opening) and neurobehavioral performance, including sensorimotor and locomotor function, anxiety and cognitive ability in the P21 rat. Treatments with minocycline significantly attenuated the hypoxia-ischemia-induced brain injury and improved neurobehavioral performance. The protection of minocycline was associated with its ability to reduce microglial activation. The present results show that minocycline has long-lasting protective effects in the neonatal rat brain in terms of both hypoxia-ischemia-induced brain injury and the associated neurological dysfunction.

    Topics: Age Factors; Animals; Animals, Newborn; Brain; Brain Damage, Chronic; Brain Infarction; Cytoprotection; Disease Models, Animal; Female; Fetal Hypoxia; Gliosis; Humans; Hypoxia-Ischemia, Brain; Infant, Newborn; Injections, Intraperitoneal; Leukomalacia, Periventricular; Male; Minocycline; Nerve Degeneration; Nerve Fibers, Myelinated; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Treatment Outcome

2006